Core Viewpoint - DNO ASA has successfully completed the acquisition of Sval Energi Group AS for USD 450 million, significantly enhancing its North Sea operations and production capacity [1][3]. Acquisition Details - The acquisition involves a portfolio of 16 producing fields in Norway, which increases DNO's North Sea production to 80,000 barrels of oil equivalent per day (boepd) and its proven and probable (2P) reserves to 189 million barrels of oil equivalent (MMboe) [2][3]. - The enterprise value of the acquisition is reported at USD 1.6 billion [1]. Production and Reserves Impact - Post-acquisition, Norway and the United Kingdom will account for nearly 60% of DNO's global production and about 45% of its global reserves, with the remainder primarily in the Kurdistan region of Iraq [3]. - The combined North Sea 2P reserves and contingent resources (2C) total 15 years of production at the current run rate [4]. Leadership and Future Growth - Halvor Engebretsen, the CEO of Sval Energi, will lead the expanded North Sea business as Managing Director of DNO Norge AS [4]. - DNO is positioned to grow its North Sea production organically, supported by ongoing field development projects and multiple discoveries [4]. Operational Performance - In Kurdistan, DNO maintains production from its Tawke license at approximately 80,000 boepd, with minimal new investment required [7]. - The company also has gas assets in Côte d'Ivoire producing over 3,000 boepd net to DNO, with plans for four development wells and one exploration well in 2025-26 [7]. Strategic Focus - DNO is actively seeking additional acquisition targets while focusing on accelerating the development and monetization of its discoveries in Norway [5][6].

Core Viewpoint - Morocco Strategic Minerals Corporation has announced positive results from a targeted rock sampling program on its BMR copper-gold property, indicating high-grade copper and notable gold and silver anomalies, suggesting potential for a larger polymetallic system [1][5]. Sampling Program Overview - The BMR Copper-Gold Property spans approximately 9 km² and features a prominent subvertical mineralized structure of about 1.2 km in length, characterized by brecciated quartz-carbonate veining with visible copper oxide minerals [2][10]. - Initial surface sampling returned values of up to 11.73% copper and 5.53 g/t gold, leading to a follow-up exploration program in May 2025, which involved collecting 67 rock samples for analysis [3][11]. Highlights from the Sampling Program - Maximum values recorded from the sampling program include 9.33% copper, 0.43 g/t gold, and 52 g/t silver, with an average copper grade of 2.82% [5][7]. - A total of 37 samples showed copper grades exceeding 2.00% Cu, while 19 samples had oxide copper grades above 2.00% CuOX, and 7 samples reported gold grades over 0.30 g/t Au [7]. Future Exploration Plans - The Corporation is planning a follow-up program that will include detailed mapping, trenching, and geophysical surveys to further assess the extent of mineralization and identify new targets across the property [6]. Property Description - The BMR Copper property is located southeast of Ouarzazate, Morocco, and is accessible via national road N9. The area has historical copper and manganese workings and is characterized by volcanic and volcano-clastic terrains [10][12]. - The southern mineralized structure is noted for its significant width and steep dip, with evidence of tectonic brecciation and the presence of massive sulfide veins [11].

Core Insights - Polyrizon Ltd. announced positive preclinical results for its hydrogel-based Trap & Target (T&T) platform, indicating effective drug delivery to the upper nasal cavity, which is crucial for central nervous system (CNS) applications [1][4] Group 1: Study Results - The study, conducted with the University of Parma, showed that Polyrizon's hydrogel formulation achieved over 60% preferential accumulation in the middle and upper turbinates, enhancing nose-to-brain transport [3] - The results suggest potential applications for CNS indications, such as opioid overdose treatment and seizure management, where rapid brain access is critical [3][4] Group 2: Technology Validation - The CEO of Polyrizon emphasized the validation of the T&T technology's ability to achieve localized deposition in favorable nasal regions, which could lead to new therapies for acute neurological and psychiatric conditions [4] - The hydrogel demonstrated consistent delivery to upper nasal segments while maintaining favorable handling characteristics, supporting further preclinical development [4] Group 3: Future Plans - Polyrizon plans to validate these preclinical results in animal models and initiate safety studies as part of its translational roadmap for the T&T technology [5]

Core Insights - Disc Medicine, Inc. is advancing its clinical programs for bitopertin, DISC-0974, and DISC-3405, with positive data presented at the EHA 2025 annual meeting, indicating favorable long-term efficacy and safety profiles for these investigational therapies [1][5][6] Bitopertin - The HELIOS study demonstrated sustained reductions in protoporphyrin IX (PPIX) and improvements in quality of life for patients with erythropoietic protoporphyria (EPP) [1][6] - Continuous treatment with 60 mg of bitopertin resulted in significant reductions in ALT and other hepatobiliary biomarkers, with nearly all participants reporting substantial quality of life improvements [6][4] - The company plans to submit a New Drug Application (NDA) for bitopertin in the second half of 2025 and has initiated a confirmatory clinical trial, APOLLO, for EPP [1][3] DISC-0974 - Data from the Phase 1b trial in myelofibrosis (MF) anemia showed sustained activity on key biomarkers and durable anemia responses among major responders [2][7] - The trial included various patient cohorts, with long-term results indicating that 50% of non-transfusion dependent patients achieved a major response with a sustained mean hemoglobin increase of ≥1.5 g/dL [10][17] - Enrollment for the Phase 2 RALLY-MF trial is ongoing, with initial data expected in the second half of 2025 [2][5] DISC-3405 - The Phase 1 trial in healthy volunteers demonstrated deep, sustained reductions in serum iron and significant changes in hematologic parameters, supporting its mechanism of action [2][9] - An iron pulse study showed that DISC-3405 inhibited dietary iron uptake, resulting in an average 94% reduction in iron absorption at Day 2 and 68% at Day 15 [12][13] - A Phase 2 trial of DISC-3405 in polycythemia vera (PV) has been initiated, with initial results anticipated in 2026 [11][17] Overall Company Strategy - The data presented at EHA supports the advancement of all three clinical candidates and highlights potential expansion opportunities into new indications [3][5] - Management will host a corporate update call on June 16, 2025, to discuss these developments further [5][3]

Kick. Sports Nutrition BELVIDERE, NJ, June 12, 2025 (GLOBE NEWSWIRE) -- Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic, and sustainable produce and products, today announced that its new Kick. Sports Nutrition line was named the 2025 Sports Nutrition Product of the Year by the prestigious Mindful Awards. The Mindful Awards honor standout companies and products across the consumer-packaged g ...

Capital structure streamlined and potential dilution from Series A Warrants eliminated ahead of key Phase 2 clinical milestonesNEW YORK and MELBOURNE, Australia, June 12, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, announces it has successfully canceled all remaining Series A Warrants pursuant to its letter agreements with the holders of the Series ...

Core Insights - America's Car-Mart, Inc. reported financial results for the fourth quarter and full year ended April 30, 2025, highlighting a period of transformation and groundwork for future growth [1][4]. Fourth Quarter Key Highlights - Total revenue increased by 1.5% to $370.2 million, driven by a 2.6% increase in sales volumes to 15,649 units and a 4.2% increase in interest income [6][11]. - Gross margin percentage improved by 90 basis points to 36.4%, attributed to optimization in vehicle pricing and procurement strategies [12][21]. - Net charge-offs as a percentage of average finance receivables improved to 6.9% from 7.3% [13][21]. - Diluted earnings per share rose to $1.26 compared to $0.06 in the previous year [6][31]. Full Year Key Highlights - Total revenue for the fiscal year was $1.4 billion, a slight decrease of 0.2% or $3.0 million from the previous year [6][33]. - Sales volumes decreased by 1.7% to 57,022 units, while interest income increased by 5.0% to $244.7 million [6][33]. - Gross margin percentage increased by 200 basis points to 36.7% [6][33]. - Net charge-offs as a percentage of average finance receivables improved to 25.9% from 27.2% [6][33]. - Active customer count increased by 2.4% to 104,682 [6][33]. Management Commentary - The President and CEO emphasized the company's agility and focus on long-term success, highlighting key accomplishments such as the expansion of the loan origination system and improvements in gross margins [4][19]. Financial Metrics - Interest expense decreased by 2.2%, while total collections increased by 3.7% to $714.1 million for the fiscal year [6][33]. - The allowance for credit losses improved to 23.25% from 25.32% year-over-year, reflecting favorable performance in contracts under enhanced underwriting standards [14][34]. - The company completed a term securitization transaction on May 29, 2025, issuing $216 million of asset-backed notes [19].

The feedback validates both the Fumed Silica Reactor and its process, while also helping identify key optimizations to enhance material quality ahead of the next phase testsMONTREAL, June 12, 2025 (GLOBE NEWSWIRE) -- HPQ Silicon Inc. (“HPQ” or the “Company”) (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08), a technology company driving innovation in advanced materials and critical process development, is pleased to inform shareholders that it has received results from testing conducted on the material shipped last week ...

MONTREAL, June 12, 2025 (GLOBE NEWSWIRE) -- PyroGenesis Inc. (“PyroGenesis”) (http://pyrogenesis.com) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), a high-tech company that designs, develops, manufactures and commercializes all-electric plasma processes and sustainable solutions to support heavy industry in their energy transition, emission reduction, commodity security, and waste remediation efforts, announces today that further to its news release dated May 28, 2025, and further to today’s press release from Pyr ...

The Company’s initial investment into the Emirate of Ras Al Khaimah comes ahead of major tourism and infrastructure developmentsNewGen plans to diversify via additional real estate investments in Abu Dhabi pending potential transactions to provide additional capital BANGKOK, June 12, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today annou ...